COVID-19 Antibody in Thai Community Hospitals

Tanawin Nopsopon, M.D.

Lecturer, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok,
Thailand

tnopsopon@gmail.com

Krit Pongpirul, M.D., M.P.H., Ph.D. (Corresponding Author)

Assistant Professor, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand; Department of International Health, Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, USA; Bumrungrad International Hospital, Bangkok, Thailand

doctorkrit@gmail.com

Korn Chotirosniramit

Medical Student, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

korn.chotiros@gmail.com

Narin Hiransuthikul, M.D., Ph.D.

Professor, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University,
Bangkok, Thailand

narin.h@chula.ac.th

Words: 1,738 words (Text), 211 words (Abstract)

Abstract

Background: COVID-19 seroprevalence data has been scarce, especially in less developed countries with a

relatively low infection rate.

Methods: A locally developed rapid IgM/IgG test kit was used for screening hospital staff and patients who

required procedural treatment or surgery in 52 hospitals in Thailand from April 8 to June 26, 2020. A total of 857

participants were tested—675 were hospital staff and 182 were pre-procedural patients. (Thai Clinical Trials

Registry: TCTR20200426002)

Results: Overall, 5.5% of the participants (47 of 857) had positive immunoglobulin M (IgM), 0.2% (2 of 857) had

positive immunoglobulin G (IgG) and IgM. Hospitals located in the central part of Thailand had the highest IgM

seroprevalence (11.9%). Preprocedural patients had a higher rate of positive IgM than the hospital staff (12.1% vs.

3.7%). Participants with present upper respiratory tract symptoms had a higher rate of positive IgM than those

without (9.6% vs. 4.5%). Three quarter (80.5%, 690 of 857) of the participants were asymptomatic, of which, 31 had

positive IgM (4.5%) which consisted of 20 of 566 healthcare workers (3.5%) and 11 of 124 preprocedural patients

(8.9%).

Conclusions: COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai

community hospitals. Antibody testing should be encouraged for mass screening, especially in asymptomatic

individuals.

MeSH Keywords: COVID-19, severe acute respiratory syndrome coronavirus 2, Seroepidemiologic Studies,

Hospitals, Thailand

Introduction

Polymerase chain reaction (PCR) was introduced as a diagnostic test of choice for coronavirus disease 2019

(COVID-19) infection. However, it might not be readily available or affordable in many facilities and could pose an

unnecessary risk to the healthcare providers during the specimen collection. Besides, a recent study raised a concern

of false-negative result from PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in

patients with high pretest probability and encouraged the development of a highly sensitive test [1]. In Thailand, the

PCR test was offered in suspected individuals with strict criteria during the initial phase of the COVID-19

pandemic. As a more feasible, cheaper, and safer alternative to the PCR, the antibody test is not only useful for an

epidemiological investigation [2] but could also be used for mass screening of potential silent spreaders—

asymptomatic COVID-19 individuals.

Hospital is one of the best venues for getting and spreading pathogens. In community hospitals in Thailand,

there are two types of people who potentially are silent spreaders and need antibody testing: (1) healthcare workers

who have a relatively higher risk of infection than laypersons, and (2) asymptomatic patients who need procedural

treatment or operation but do not meet the criteria for PCR testing.

Methods

From April 8 to June 26, 2020, hospital staff and patients who needed procedural treatment or operation but did not

meet the national PCR testing criteria in 244 hospitals (215 community and 29 general hospitals) from all regions of

Thailand were offered antibody testing. Of 215 community hospitals, data from 52 community hospitals (24.2%) in

35 provinces were readily available for the analysis performed on June 29, 2020. Patients with PCR confirmed

COVID-19 infection were quarantined and excluded. Baiya Rapid COVID-19 IgG/IgM test kit (Baiya Phytopharm,

Thailand) which reports the presence of immunoglobulin M (IgM) and immunoglobulin G (IgG) qualitatively, was

used in this study free of charge. The internal validation of the test kit using the serum of 51 PCR confirmed

COVID-19 cases and 150 controls showed sensitivity 94.1% (48 of 51) and specificity 98.0% (147 of 150) for IgM

or IgG antibody. Participants with positive IgM were encouraged to have PCR test if available.

Statistical analysis

Categorical data were presented with counts and percentages while continuous data were provided with median and

interquartile range. The 95% confidence interval (CI) of the seroprevalence was calculated by Wilson's method

using binomial probabilities. Missing data were excluded. A two-tailed p < 0.05 was considered statistically

significant. All data were analyzed using Stata 16.1 (College Station, TX).

Ethics Committee Approval

This study was approved by the Institutional Review Board of Chulalongkorn University (IRB No.236/63) and 18

general hospitals. Given no ethics committees were available in the participating community hospitals, participation

in this study was approved by the hospital directors or representatives. (Thai Clinical Trials Registry:

TCTR20200426002)

Results

From 52 community hospitals, 857 participants which consisted of 675 hospital staff and 182 pre-procedural

patients were included in the study. Their median age was 37 years (interquartile range 27–45), 74.7% were female,

98.8% were Thai, and 80.5% were asymptomatic. The most common symptoms were cough (9.7%), rhinitis (7.5%),

sore throat (6.4%), fever (5.7%) and dyspnea (3.5%). History of travel to the high-risk area was 6.0%, history of

close contact to the confirmed COVID-19 case was 15.4%, and 14.5% had PCR negative. Forty-seven participants

(5.5%, 95% CI 4.1–7.2) had IgM antibody against SARS-CoV-2 whereas IgG antibody was found in two

participants (0.2%, 95% CI 0.1–0.8). Participants from the Central region of Thailand had the highest IgM

seroprevalence (11.9%, 95% CI 8.4–16.5), while the Northern region had the lowest seroprevalence (1.6%, 95% CI

0.3–8.7) [Fig 1].

Thailand	5.5%
Northern	1.6%
Northeastern	3.0%
Central	11.9%
Southern	1.8%
Eastern	4.0%

Powered by Bing
© GeoNames, Microsoft, TomTom

Seroprevalence (%)

0   50   100

Fig 1. IgM seroprevalence in 52 community hospitals across geographical regions of Thailand.

Pre-procedural patients had an unexpectedly higher proportion of positive IgM than the hospital staff (12.1% vs. 3.7%), especially patients in the Central region of Thailand (27.9%, 95% CI 18.2–40.2) while patients in the Northern and Southern regions showed zero seroprevalences. Also, hospital staffs in the Central of Thailand had the highest seroprevalence (6.6%, 95% CI 3.8–11.1) while those in the Northern had the lowest (1.7%, 95% CI 0.3–9.0). Overall, the seropositive prevalence was not different between male and female (5.8% vs. 5.5%). Paradoxically, the seroprevalences were higher in participants without a history of travel to the high-risk area (5.6% vs. 3.9%) and those without a history of close contact to confirmed COVID-19 case (5.7% vs. 4.5%) than their

counterparts. The same paradox also applied to pre-procedural patients. Patients without travel history were likely to

have an antibody for SARS-CoV-2 (13.9% vs. 3.2%) and patients without close contact to the case also had more

chance to develop an antibody (12.3% vs. 9.1%). However, healthcare workers with travel history had slightly more

chance to develop IgM (5.0% vs. 3.7%) and also with close contact history (4.1% vs. 3.6%). In general, participants

with upper respiratory tract symptoms had a higher chance of being seropositive (9.6% vs. 4.5%), of which dyspnea

had the highest (30.0%, 95% CI 16.7–47.9). Likewise, pre-procedural patient with dyspnea had the most IgM

positive (29.6%, 95% CI 15.9–48.5) and also healthcare worker with dyspnea (33.3%, 95% CI 6.1–79.2). Of 690

participants without present upper respiratory tract symptom, 31 had IgM positive for COVID-19 (4.5%, 95% CI

3.2–6.3) which consisted of 20 of 566 healthcare workers (3.5%, 95% CI 2.3–5.4) and 11 of 124 patients (8.9%,

95% CI 5.0–15.2). History of negative PCR was associated with a surprisingly higher chance of seropositive than

those with no PCR test result (6.5% vs. 5.3%) [Table 1]. Unfortunately, none of the participants with positive IgM

had opportunities for PCR testing.

IgG was detected in two participants (0.2%, 95% CI 0.1–0.8) who also had positive IgM antibody. In other

words, we did not find any participants with an isolated positive IgG. Participant A was a Thai female healthcare

worker who worked in a community hospital in the Central region of Thailand. She had a sore throat but had no

history of travel to a high-risk area or close contact to confirmed COVID-19 case, and did not have PCR test before.

Participant B was a Thai female preprocedural patient who visited another community hospital in the Central part of

Thailand. She had no symptom, no history of travel to a high-risk area or close contact to confirmed COVID-19

case. Patient B had a previously negative PCR result [Table 2].

Table 1. Demographic characteristics and seroprevalence in different groups

	All participant		Hospital Staff		Pre-procedural Patients	
	n	IgM+	n	IgM+	n	IgM+
Total	857	47 (5.5%)	675	25 (3.7%)	182	22 (12.1%)
Median age, years (25th–75th percentile)	37 (27–45)		36.5 (28–45)		37 (25–53)	
Male, n (%)	207 (24.1%)	12 (5.8%)	145 (21.5%)	6 (4.1%)	62 (34.1%)	6 (9.7%)
Female, n (%)	640 (74.7%)	35 (5.5%)	521 (77.2%)	19 (3.6%)	119 (65.4%)	16 (13.4%)
Unspecified, n (%)	10 (1.2%)	0 (0.0%)	9 (1.3%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
Thai	847	47 (5.5%)	671	25 (3.7%)	176	22 (12.5%)
Non-Thai	10	0 (0.0%)	4	0 (0.0%)	6	0 (0.0%)
Region						
North	61	1 (1.6%)	59	1 (1.7%)	2	0 (0.0%)
Northeast	269	8 (3.0%)	220	4 (1.8%)	49	4 (8.2%)
Central	244	29 (11.9%)	183	12 (6.6%)	61	17 (27.9%)
South	109	2 (1.8%)	88	2 (2.3%)	21	0 (0.0%)
East	174	7 (4.0%)	125	6 (4.8%)	49	1 (2.0%)
History of travel to high risk area						
Yes	51	2 (3.9%)	20	1 (5.0%)	31	1 (3.2%)
No	806	45 (5.6%)	655	24 (3.7%)	151	21 (13.9%)
History of close contact confirmed case						
Yes	132	6 (4.5%)	121	5 (4.1%)	11	1 (9.1%)
No	725	41 (5.7%)	554	20 (3.6%)	171	21 (12.3%)
Asymptomatic	690	31 (4.5%)	566	20 (3.5%)	124	11 (8.9%)
Symptomatic	167	16 (9.6%)	109	5 (4.6%)	58	11 (19.0%)
Fever	49	7 (14.3%)	17	0 (0.0%)	32	7 (21.9%)
Cough	83	8 (9.6%)	52	1 (1.9%)	31	7 (22.6%)
Rhinitis	64	7 (10.9%)	47	2 (4.3%)	17	5 (29.4%)
Sore throat	55	8 (14.5%)	37	3 (8.1%)	18	5 (27.8%)
Dyspnea	30	9 (30.0%)	3	1 (33.3%)	27	8 (29.6%)
Previous PCR status						
Negative	124	8 (6.5%)	77	1 (1.3%)	47	7 (14.9%)
Never tested	733	39 (5.3%)	598	24 (4.0%)	135	15 (11.1%)

115   Data were presented in counts and percentages unless otherwise specified.
116   IgM+, immunoglobulin M positive; NA, not available; PCR, polymerase chain reaction.

118   **Table 2.** Main characteristics of participants who developed COVID-19 IgG antibody

	Age Range, years	Gender	Ethnicity	Region	Occupation	History of travel to high risk area	History of contact confirmed case	Symptoms	Previous PCR status
Participant A	56-60	Female	Thai	Central	HCW	No	No	Sore throat	Never tested
Participant B	41-45	Female	Thai	Central	Patient	No	No	No	Negative

HCW, healthcare worker; PCR, polymerase chain reaction; Age range was used for participant's privacy and confidentiality.

Discussion

COVID-19 seroprevalence in asymptomatic staff and patients in Thai community hospitals was higher than

hospitals in China (4.5% vs. 2.5%) [3]. Seroprevalence in asymptomatic hospital staff in Thailand was also higher

than hospitals in China (3.5% vs. 1.8%) [3] but less than a tertiary hospital in Belgium (3.5% vs. 6.4%) [4].

Asymptomatic patients in Thailand seemed to have higher seroprevalence than China (8.9% vs. 3.5%) [3]. Unlike

China and Belgium where the seroprevalences were mostly from positive IgG, our study revealed mostly positive

IgM. Comparison with Belgium hospital should be interpreted with caution due to unknown PCR status of Belgium

subjects.

Serological testing provides some crucial epidemiological information and would have been more effective

when combined with other diagnostic tests such as PCR. While all participants with a positive result from the free-

of-charge rapid IgM/IgG test provided in this study were encouraged to get PCR testing, a majority of community

hospitals still did not have access to the PCR testing because of both financial and non-financial reasons.

Recommendation for PCR testing after positive rapid IgM/IgG test had not fully complied so we did not have

information about any participant with positive IgM. With immunoglobulin status and PCR results, we can shape the

situation more accurately for both individual, institutional, and regional views. Hopefully, with this and other

vigorous and dedicated studies on antibody status around the globe, serology testing would provide useful

information for pandemic control.

Conclusions

COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals.

Antibody testing should be encouraged for mass screening, especially in asymptomatic individuals.

Acknowledgements

We thank Baiya Phytopharm, Thailand for supporting the Baiya Rapid COVID-19 IgG/IgM test kit. The company

did not involve in the data analysis, interpretation, and manuscript preparation.

Author Contributions

Conceptualization: TN, KP, NH

Data curation: TN, KC, KP

Formal analysis: TN, KP

Investigation: TN, KC, KP

Methodology: TN, KP, NH

Project administration: TN, KP, NH

Resources: KP, NH

Software: TN, KP

Supervision: KP, NH

Validation: TN, KC, KP

Visualization: TN

Writing – original draft: TN, KP

Writing – review & editing: TN, KP, KC, NH

References

1. Woloshin S, Patel N, Kesselheim A. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med. 2020. Epub 2020/06/06. doi: 10.1056/NEJMp2015897. PubMed PMID: 32502334.

2. Yong S, Anderson D, Wei W, Pang J, Chia W, Tan C, et al. Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infect Dis. 2020. Epub 2020/04/25. doi: 10.1016/s1473-3099(20)30273-5. PubMed PMID: 32330439; PubMed Central PMCID: PMCPMC7173813.

3. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020. Epub 2020/06/07. doi: 10.1038/s41591-020-0949-6. PubMed PMID: 32504052.

4. Steensels D, Oris E, Coninx L, Nuyens D, Delforge M, Vermeersch P, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. Jama. 2020. Epub 2020/06/17. doi: 10.1001/jama.2020.11160. PubMed PMID: 32539107.